Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn

STOCKHEAD

MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC to 100 per cent CBD products when treating severe intractable epilepsy.

Read more :

More to explorer

Leave a Reply